← Back to Search

Telemedicine Follow-Up and Telemedicine Monitoring for Inflammatory Bowel Disease

N/A
Waitlist Available
Led By Geoffrey C Nguyen
Research Sponsored by Mount Sinai Hospital, Canada
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Ability to provide informed consent
Confirmed diagnosis of Crohn's Disease or Ulcerative Colitis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 30 days of study enrolment
Awards & highlights

Study Summary

Inflammatory Bowel Diseases (IBD) refers to a category of disorders, consisting of Crohn's Disease (CD) and Ulcerative Colitis (UC), where segments of the gastrointestinal tract become inflamed and ulcerated. Canada has among the highest incidence rates of IBD in the world - 16.3 and 12.3 per 100,000 for CD and UC respectively. In the absence of a cure, the current goal of treatment is to manage patients in a milder state of remission. However, maintaining (or even achieving) remission is dependent on timely access to specialist IBD care; which in light of rising incidence rates have proven to be challenging. Moreover, patients often experience flare-ups of their gastrointestinal symptoms, while awaiting access to specialist care. In recent years, there has been increased integration of telemedicine services in gastroenterology practice. This change has been driven by a desire among IBD patients to have more flexible follow-up care, where 'virtual' care is provided as an adjunct to in-person consultations. Within the context of IBD, telemedicine might be effective in delivering routine and timely follow-up care to high-risk patients. The purpose of this study to determine whether telemedicine-based follow-up care can effectively manage the gastrointestinal symptoms of high-risk IBD patients and reduce their need for preventive health care services.

Eligible Conditions
  • Inflammatory Bowel Disease
  • Crohn's Disease
  • Ulcerative Colitis

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 30 days of study enrolment
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 30 days of study enrolment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Post-Appointment IBD related Hospital Admission
Secondary outcome measures
Disease Activity
IBD related Quality of Life
Patient Satisfaction with Health Care in IBD
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Telemedicine Follow-Up and Telemedicine MonitoringExperimental Treatment3 Interventions
Group II: Minimal InterventionActive Control1 Intervention

Find a Location

Who is running the clinical trial?

Mount Sinai Hospital, CanadaLead Sponsor
194 Previous Clinical Trials
66,954 Total Patients Enrolled
Crohn's and Colitis CanadaOTHER
7 Previous Clinical Trials
882 Total Patients Enrolled
Geoffrey C NguyenPrincipal InvestigatorMOUNT SINAI HOSPITAL

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~72 spots leftby Mar 2025